Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)
Recruiting now · Phase 4 · Has a placebo group
Conditions studied: Ischemic Stroke
In brief
EXCELLENT was a prospective, multicenter, randomized, double-blind, placebo-controlled clinical study in which participants were randomized participants were randomized (1:1) to receive either IV thrombolysis + edaravone or IV thrombolysis + matched placebo (same volume of tablets without drug components), and the primary outcome was the proportion of patients with transformed bleeding on MRI at 72 hours following revascularization therapy.
Key facts
- Study ID
- NCT07119021
- Run by
- Ruijun Ji
- People needed
- 300
- Starts
- 2024-08-01
- Expected to finish
- 2027-07-31
- Last updated by the study team
- 2025-08-12
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18-80 years;
- Acute ischemic stroke as defined by the International Health Organization (WHO) and confirmed by cranial CT;
- Onset within a 4.5-hour time window;
- NIHSS score of 6-24;
- Meet the criteria for intravenous thrombolysis in acute ischemic stroke recommended by international guidelines;
- Patient or family consent.
You may not qualify if…
- Pregnant women, women in labor, and patients in the puerperium;
- Comorbidity with other serious diseases that affect outcome determination;
- Comorbidity with other serious diseases that affect prognostic regression;
- Comorbidity with other serious diseases with a life expectancy of less than 1 year;
Where it is running
- Beijing Tiantan Hospital of Capital Medical University — Beijing, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.